Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 657-662

  Leibowitz Amit, R ^a   Templeton, A J ^a   Omlin, A ^b   Pezaro, C ^b   Atenafu, E G ^a   Keizman, D ^c   Vera Badillo, F ^a   Seah, J A ^a   Attard, G ^b   Knox, J J ^a   Sridhar, S S ^a   Tannock, I F ^a   De Bono, J S ^b   Joshua, A M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

Abiraterone acetate; MCRPC; NLR; Prostate cancer; Response

Indexed keywords

ABIRATERONE ACETATE; DEXAMETHASONE; LACTATE DEHYDROGENASE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; HEMATOLOGICAL PARAMETERS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUTROPHIL; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION PROCESS;

ABIRATERONE ACETATE; MCRPC; NLR; PROSTATE CANCER; RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANDROSTADIENES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; L-LACTATE DEHYDROGENASE; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEUTROPHILS; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896813535     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt581     Document Type: Article

References (20)

1. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
2. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
3. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
4. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
5. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
6. Keizman D, Gottfried M, Ish-Shalom M et al. Pretreatment neutrophil-tolymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist 2012; 17: 1508-1514.
7. Roach M, 3rd, Hanks G, Thames H Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-974.
8. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
9. Floyd M, Muckle TJ, Kerr DN. Prednisone-induced leucocytosis in nephrotic syndrome. Lancet 1969; 1: 1192-1193.
10. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970.
11. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
12. Guthrie GJ, Charles KA, Roxburgh CS et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-230.
13. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 2013; 23: 200-207.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
15. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol 2013; 35: 163-176.
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
17. Donskov F, Bennedsgaard KM, Von Der Maase H et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002; 87: 194-201.
18. Olmos D, Brewer D, Clark J et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol 2012; 13: 1114-1124.
19. Lee Y, Kim SH, Han JY et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol 2012; 138: 2009-2016.
20. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28: 4247-4254.